Literature DB >> 21840177

Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia.

Cort A Pedersen1, Clare M Gibson, Shane W Rau, Kayvon Salimi, Kelly L Smedley, Robin L Casey, Jane Leserman, L Fredrik Jarskog, David L Penn.   

Abstract

Oxytocin has numerous prosocial and antipsychotic-like effects in animals. Prosocial effects of acute intranasal oxytocin administration have also been reported in human subjects. We conducted a randomized, placebo-controlled trial testing the effects of twice daily intranasal oxytocin treatment for 14 days on psychotic symptoms and social cognition in patients with schizophrenia. PANSS scores declined significantly and several social cognition measures improved significantly or nearly significantly in oxytocin (N=11) but not placebo (N=9) recipients. Our results suggest that, in addition to reducing classic psychotic symptoms, oxytocin may diminish certain social cognition deficits that are not improved by current antipsychotic medications.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840177     DOI: 10.1016/j.schres.2011.07.027

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  104 in total

Review 1.  Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials.

Authors:  Kazuto Oya; Yuki Matsuda; Shinji Matsunaga; Taro Kishi; Nakao Iwata
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-25       Impact factor: 5.270

Review 2.  Oxytocin and social cognition in affective and psychotic disorders.

Authors:  M Mercedes Perez-Rodriguez; Katie Mahon; Manuela Russo; Allison K Ungar; Katherine E Burdick
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

3.  Effects of Oxytocin on Neural Response to Facial Expressions in Patients with Schizophrenia.

Authors:  Na Young Shin; Hye Yoon Park; Wi Hoon Jung; Jin Woo Park; Je-Yeon Yun; Joon Hwan Jang; Sung Nyun Kim; Hyun Jung Han; So-Yeon Kim; Do-Hyung Kang; Jun Soo Kwon
Journal:  Neuropsychopharmacology       Date:  2015-02-10       Impact factor: 7.853

4.  Adapting social neuroscience measures for schizophrenia clinical trials, Part 1: ferrying paradigms across perilous waters.

Authors:  Michael F Green; Junghee Lee; Kevin N Ochsner
Journal:  Schizophr Bull       Date:  2013-09-26       Impact factor: 9.306

Review 5.  [Oxytocin: evidence for a therapeutic potential of the social neuromodulator].

Authors:  M Eckstein; R Hurlemann
Journal:  Nervenarzt       Date:  2013-11       Impact factor: 1.214

Review 6.  The role of oxytocin in psychiatric disorders: a review of biological and therapeutic research findings.

Authors:  David M Cochran; Daniel Fallon; Michael Hill; Jean A Frazier
Journal:  Harv Rev Psychiatry       Date:  2013 Sep-Oct       Impact factor: 3.732

7.  Oxytocin reactivity to an emotional challenge paradigm and its relation to social-cognitive functions in healthy volunteers.

Authors:  Nina Kampka; Nicole Frommann; Uwe Henning; Robert Schwark; Wolfgang Wölwer; Reinhard Pietrowsky; Christian Luckhaus
Journal:  J Neural Transm (Vienna)       Date:  2018-12-11       Impact factor: 3.575

8.  A Predictive Coding Account of Psychotic Symptoms in Autism Spectrum Disorder.

Authors:  Gerrit I van Schalkwyk; Fred R Volkmar; Philip R Corlett
Journal:  J Autism Dev Disord       Date:  2017-05

9.  Effects of oxytocin on working memory and executive control system connectivity in posttraumatic stress disorder.

Authors:  Julianne C Flanagan; Anne Hand; Amber M Jarnecke; Megan M Moran-Santa Maria; Kathleen T Brady; Jane E Joseph
Journal:  Exp Clin Psychopharmacol       Date:  2018-08       Impact factor: 3.157

Review 10.  Research review: Social motivation and oxytocin in autism--implications for joint attention development and intervention.

Authors:  Katherine K M Stavropoulos; Leslie J Carver
Journal:  J Child Psychol Psychiatry       Date:  2013-03-02       Impact factor: 8.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.